|
(Health-NewsWire.Net, October 28, 2020 ) The Pharmaceutical Contract Development and Manufacturing Market is expected to reach USD 126.6 billion by 2024 from USD 90.0 billion in 2019, at a CAGR of 7.1%. The major factors driving the growth of this market are the rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs.
By service, the pharmaceutical manufacturing segment is expected to account for the largest share of the pharmaceutical contract development and manufacturing market
The pharmaceutical manufacturing segment is estimated to account for the largest market share in 2019. The large share of this segment can be attributed to the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, growing demand for generic drugs, high cost of operations, and lack of in-house manufacturing capacity. This segment includes pharmaceutical API manufacturing and pharmaceutical FDF manufacturing.
In the biologics manufacturing services market, by type, the biologic FDF manufacturing segment is expected to grow at the highest CAGR during the forecast period
The biologic FDF manufacturing segment is expected to grow at the highest CAGR during the forecast period. The growth in this segment can be attributed to factors such as the increasing R&D costs, changing product pipelines, growing importance of biologics and biosimilars, and process complexity.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=201524381
On the basis of the end user, the big pharma segment is expected to account for the largest share of the pharmaceutical contract development and manufacturing market
The big pharma end-user segment is estimated to account for the largest market share in 2019. The large share of this segment can be attributed to the emergence of new medicines and therapy forms, pricing pressure, pipeline challenges, and growth opportunities in emerging markets.
The Asia Pacific is estimated to be the fastest-growing market for pharmaceutical contract development and manufacturing during the forecast period
The APAC market is projected to register the highest growth during the forecast period. Factors such as the growth of its manufacturing sector, favorable government regulations, expansions by leading companies, increasing emphasis on off-patent drugs, and a highly skilled workforce are some of the key factors driving the growth of the pharmaceutical contract development and manufacturing market in the APAC.
The prominent players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
